Affimed (NASDAQ:AFMD) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Affimed (NASDAQ:AFMD) in a report released on Sunday. The firm issued a sell rating on the biopharmaceutical company’s stock.

Affimed Trading Down 80.7%

Shares of NASDAQ AFMD opened at $0.13 on Friday. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.93 and a quick ratio of 1.93. Affimed has a 52-week low of $0.13 and a 52-week high of $8.95. The business’s 50 day moving average is $0.78 and its two-hundred day moving average is $1.47.

Institutional Trading of Affimed

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Northern Trust Corp purchased a new stake in Affimed in the fourth quarter valued at approximately $218,000. Intellectus Partners LLC raised its position in Affimed by 34.0% in the fourth quarter. Intellectus Partners LLC now owns 126,414 shares of the biopharmaceutical company’s stock valued at $150,000 after purchasing an additional 32,053 shares during the period. Finally, Jane Street Group LLC purchased a new stake in Affimed in the third quarter valued at approximately $44,000. Hedge funds and other institutional investors own 30.82% of the company’s stock.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.